account_id none on file
legal_name TScan Therapeutics, Inc.
ticker TCRX
cik 1783328
domain tscan.com
linkedin_company_url https://www.linkedin.com/company/tscan-therapeutics
entry_point_account_id none on file
name TScan Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 2 family 0
why_nownone on file
callsnone on file
filings
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / Aug 12, 2026 / receipt
healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.
filing / Aug 12, 2026 / receipt
In addition, we may not achieve the anticipated benefits and savings from the workforce reduction. On November 3, 2025, the Company announced a prioritization strategy and pursuant to this strategy, the Company also implemented a workforce reduction of approximately 30%, or 66 roles.
filing / Aug 12, 2026 / receipt
On November 3, 2025, the Company announced a prioritization strategy and pursuant to this strategy, the Company also implemented a workforce reduction of approximately 30%, or 66 roles.
filing / Aug 12, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / May 6, 2026 / receipt
healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications.
filing / May 6, 2026 / receipt
In addition, we may not achieve the anticipated benefits and savings from the workforce reduction. On November 3, 2025, the Company announced a prioritization strategy and pursuant to this strategy, the Company also implemented a workforce reduction of approximately 30%, or 66 roles.
filing / May 6, 2026 / receipt
On November 3, 2025, the Company announced a prioritization strategy and pursuant to this strategy, the Company also implemented a workforce reduction of approximately 30%, or 66 roles.
filing / May 6, 2026 / receipt
executives
| Leiden Dworak | Principal Accounting Officer | - | receipt |
| Stephen Biggar | Chairman of the Board | - | receipt |
familynone on file
upcoming
changes
| 2025-08-20 | Principal Accounting Officer, appointed | sec_8k |
| 2024-06-14 | Chairman of the Board, appointed | sec_8k |
| 2023-07-25 | Principal Accounting Officer, appointed | sec_8k |
| 2023-03-31 | Chief Executive Officer, departed | sec_8k |
mcp_package_hint
slug tscan-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$